key: cord-0953737-fqd36hjc
authors: Levy, David; Lebreton, Guillaume; Pineton de Chambrun, Marc; Hékimian, Guillaume; Chommeloux, Juliette; Bréchot, Nicolas; Luyt, Charles-Edouard; Leprince, Pascal; Combes, Alain; Schmidt, Matthieu
title: Outcomes of Patients Denied Extracorporeal Membrane Oxygenation during the COVID-19 Pandemic in Greater Paris, France
date: 2021-03-30
journal: Am J Respir Crit Care Med
DOI: 10.1164/rccm.202105-1312le
sha: c9a084c4c861295ea0292ffe298d0c736c29a88f
doc_id: 953737
cord_uid: fqd36hjc

nan

between March 8, 2020, and June 3, 2020. At least two intensivists discussed each patient's case and decided among the following: "ECMO, yes" (i.e., prompt cannulation by a local or a mobile ECMO team); "ECMO, no, not yet" because criteria for ECMO were not met; or "ECMO, no, never," because of an anticipated poor prognosis despite ECMO (5) . When an "ECMO, no, not yet" decision was made, advice to optimize patients' management and mechanical ventilation settings were given, with a possibility to reevaluate later ECMO indication.

Patients' characteristics among the three groups were compared by ANOVA. Kaplan-Meier survival curves were computed and compared using log-rank tests. Follow-up started from the decision to initiate ECMO or not. The study was approved by the local ethical committee, Comit e d'Ethique de la Recherche of Sorbonne University (#CER-SU-2020-69).

Of the 575 cases from 75 centers submitted to the ECMO-COVID-19 hub, 302 (53%) patients met eligibility criteria and received ECMO (4), of whom 12 received ECMO after an initial "ECMO, no, not yet" decision. These 12 patients were included in the "ECMO, yes" group. ECMO was denied to 273 (48%) patients after a first call, of whom 15 had too many missing data and 12 received ECMO secondarily (i.e., they were included in the "ECMO, yes" group for the analysis). Reasons for ECMO refusals in the 162 (66%) "ECMO, no, never" patients were mechanical ventilation .10 days (n = 68), age .65 years (n = 53), multiple organ failure (n = 32), immunosuppression (n = 23), or severe disability due to extreme obesity (n = 16). For 35 of 68 patients, mechanical ventilation .10 days was the only reason for being denied ECMO, whereas 27 of 53 patients were denied only because of being aged .65 years. "ECMO, no, not yet" was advised for 84 (34%) patients. Characteristics and outcomes of patients are provided in Table 1 . Briefly, "ECMO, yes" patients were younger, had a shorter time between intubation and ECMO-COVID-19 hub call, and had a higher Respiratory ECMO Survival Prediction score than patients denied ECMO (P , 0.01). Compared with the two other patient groups, "ECMO, no, not yet" patients had significantly lower driving pressure and higher Pa O 2 /FI O 2 ratio and lung static compliance (both P , 0.01). They also were more frequently on renal replacement therapy. Ninety-day survival ( Figure 1 ) was obtained for 233 of 246 patients denied ECMO (i.e., 83 "ECMO, no, not yet" and 150 "ECMO, no, never" patients) and was not different between "ECMO, yes" and "ECMO, no, not yet" patients (49% vs. 46%; log-rank test, P = 0.93). However, the 90-day survival of "ECMO, no, never" patients was significantly lower than the two other groups (14%; log-rank test, P , 0.001). Compared with "ECMO, no, not yet" and "ECMO, no, never" patients, "ECMO, yes" patients had a significantly longer stay in the ICU ( Our study reports the characteristics and outcomes of patients with COVID-19 with severe ARDS referred for ECMO decision during the first wave of the pandemic in Greater Paris. A similar 90-day survival was observed for patients who received ECMO and those for whom ECMO was not yet indicated. Alternatively, patients considered not suitable for ECMO had a very low 90-day survival.

The decision to initiate ECMO in patients with severe ARDS remains complex, especially in the context of a pandemic with a shortage of resources and ICU beds and of a new disease, for which mid-term and long-term outcomes are still unknown. Ideally, the decision should be based on scientific evidence and the ability to identify patients more likely to benefit from ECMO. The similar survival rate observed in "ECMO, yes" and "ECMO, no, not yet" patients is reassuring and validates a posteriori the restrictive ECMO selection criteria that we defined for patients with COVID-19. However, a sizeable proportion of patients in the "ECMO, no, not yet" group may have received ECMO before the pandemic (3), and we cannot exclude that early ECMO may have improved their outcomes. The very low survival rate of "ECMO, no, never" patients is in agreement with series evaluating outcome predictors of patients with COVID-19 and severe ARDS (6) . These patients were older, had more comorbidities, had spent more days on mechanical ventilation, and had signs of more severe lung disease. Although not all of them died, the probability of ECMO saving many lives in this group is obviously lower. The substantial proportion of ECMO refusal that occurred only because of mechanical ventilation .10 days could advocate for an earlier call to the ECMO center, although we cannot ensure that criteria for ECMO initiation had already been met in the days preceding the call.

Our study has some limitations. Data were collected mainly on the day of the call to the ECMO-COVID-19 hub, with no information regarding complications and organ dysfunction that occurred during the ICU stay in patients who were denied ECMO. Our study also took place during the first wave of the pandemic in France. The management of patients with COVID-19 in later phases of the pandemic, with more frequent use of dexamethasone and tocilizumab and more frequent and longer recourse to noninvasive ventilation strategies before intubation, may have changed the outcomes of our three patient groups (7) (8) (9) .

In conclusion, the Greater Paris ECMO hub-and-spoke network, which first defined criteria for ECMO and then regulated and centralized ECMO indications during the COVID-19 pandemic, appropriately selected patients who were more likely to benefit from the technique (10). 

To the Editor:

Chronic obstructive pulmonary disease (COPD) and asthma are major sources of morbidity and mortality. Inhaled bronchodilators are a cornerstone of disease management, but treatment is not equally effective in all patients (1, 2) . Identifying factors associated with bronchodilator efficacy may expand opportunities for precision medicine and, critically, identify patient subgroups for which new therapies are urgently needed. The airway tree is the target of inhaled therapies. Using computed tomography (CT), we have demonstrated that variation in native airway tree caliber relative to lung size (i.e., dysanapsis) is common in the general population (3), extends to the peripheral airways (4), and is associated with COPD risk (3). Although computational fluid dynamic studies of particle deposition (5) suggest that dysanapsis may modify inhaled pharmacotherapy efficacy, in vivo evidence is lacking.

This study evaluated whether dysanapsis quantified by CT is associated with the spirometric response to a standardized dose of inhaled bronchodilator.

Participants. The COLD (Canadian Obstructive Lung Disease) prevalence study used census data to recruit a random sample of noninstitutionalized adults >40 years old from nine communities (2005) (2006) (2007) (2008) (2009) ). In 2010-2014, the ongoing CanCOLD (Canadian Cohort Obstructive Lung Disease) study enrolled COLD participants with COPD, and representative random subsets of COLD nonsmoking and smoking participants without COPD matched on age and sex (6) . Data from the baseline CanCOLD visit were included in this analysis. Institutional review board approval was obtained, and all participants provided written informed consent.

CT assessment of dysanapsis. Full-inspiration CT was performed on helical scanners according to a standardized protocol. Airway lumen diameters at 19 standard anatomic locations (tracheato-subsegments) and total lung volume were measured from CT images using Apollo Software (VIDA Diagnostics) by trained readers unaware of other participant information. Trained readers achieved a minimum training set interrater intraclass correlation of 0.9 (3).

Dysanapsis was quantified as the mean of airway lumen diameters in centimeters divided by the cube root of total lung volume in cubic centimeters (airway-to-lung ratio). Lower values of airway-to-lung ratio indicate smaller airway tree-to-lung size, and higher values indicate larger airway tree-to-lung size. Secondary dysanapsis measures were percent-predicted airway tree caliber calculated from reference equations that account for age, sex, height, and lung volume (3), and the mean of airway lumen diameters in centimeters.

Lung function. Spirometry was performed before and 15 minutes after inhalation of 200 mg of salbutamol (albuterol) that was administered from a metered-dose inhaler with spacer device (100 mg/actuation) (7). Participants were instructed to not use regular inhaled medications 6-24 hours before spirometry depending on medication class. Spirometric COPD was defined by post-bronchodilator FEV 1 /FVC ,0.7 (1). Bronchodilator-associated change in FEV 1 (DFEV 1 ) and FEV 1 / FVC (DFEV 1 /FVC) were calculated as post-bronchodilator minus prebronchodilator values.

Other variables. Age, sex, cigarette smoking status, and regular inhaled medication use were self-reported. Clinical diagnoses of asthma and COPD corresponded to an affirmative response to 

Extracorporeal Life Support Organization. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry

Groupe de Recherche Clinique en REanimation et Soins intensifs du Patient en Insuffisance Respiratoire aiguE (GRC-RESPIRE) Sorbonne Universit e; Paris-Sorbonne ECMO-COVID investigators. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study

EOLIA Trial Group; REVA; and ECMONet. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome

ECMO-COVID-19 investigators. Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study

Saying no until the moment is right: initiating ECMO in the EOLIA era

Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study

Dexamethasone in hospitalized patients with Covid-19

Tocilizumab in hospitalized patients with severe Covid-19 pneumonia

ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19-final report

Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases